Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.57 |
| ▸ | CA9 | Q16790 | 8/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6934958 | 0.76 | KDM4E (0.42) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL31139188 | 0.73 | MAOB (0.73) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL6155496 | 0.73 | MAOB (0.73) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL18073979 | 0.73 | CA12 (1.00) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL5345045 | 0.73 | MAOB (0.77) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL6938071 | 0.73 | HSP90AB1 (0.46) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL6938077 | 0.73 | HSP90AB1 (0.46) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL4187220 | 0.72 | MAOB (1.00) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL6865603 | 0.71 | KDM4E (0.64) | CA12CA9TNFNOD2NOD1 | |
| SCHEMBL22840392 | 0.70 | MAOB (0.67) | CA12CA9TNFNOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583119-B2 | Aromatic antibiotics such as 7-((6-deoxy-5-methyl-4-methyl-hexopyranosyl)oxy)-4-hydroxy-8-methyl-3-(1 -(phenoxyimino) ethyl)-2H-1-benzopyran-2-one (2-propynyloxy)-carbamic 3'-ester acid, for prevention of grampositive bacterial infections | AVENTIS PHARMA S.A. (FR) | 2003-06-24 | — | — | US | disclosed |
| US-6579902-B1 | Antibiotic; ethoxy-carbamic acid 3'-ester of N-(7-((6-deoxy-5-C-methyl-4-O- methyl-alpha-L-lyxo-hexopyranosyl)oxy)-4-hydroxy-8-methyl-2-oxo-2H-1 -benzopyran-3-yl)-benzeneacetamide | AVENTIS PHARMA S.A. (FR) | 2003-06-17 | — | — | US | disclosed |
| EP-1045856-B1 | NOVEL AROMATIC AMIDES, PREPARATION METHOD AND APPLICATION AS MEDICINES | AVENTIS PHARMA SA (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-20030060609-A1 | Novel aromatic amides, preparation method and application as medicines | AVENTIS PHARMA S.A. | 2003-03-27 | — | — | US | disclosed |
| US-6420538-B1 | COMPOUND FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
| EP-1173455-A2 | NOVEL RIBOSE-SUBSTITUTED AROMATIC AMIDES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma S.A. (FR) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000063222-A2 | NOVEL RIBOSE-SUBSTITUTED AROMATIC AMIDES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA S.A. (FR) | 2000-10-26 | — | — | WO | disclosed |
| EP-1045856-A1 | NOVEL AROMATIC AMIDES, PREPARATION METHOD AND APPLICATION AS MEDICINES | HOECHST MARION ROUSSEL (FR) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035155-A1 | NOVEL AROMATIC AMIDES, PREPARATION METHOD AND APPLICATION AS MEDICINES | HOECHST MARION ROUSSEL (FR) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060609-A1 | Novel aromatic amides, preparation method and application as medicines | NRDC, NPR1, NR4A1 | CA12 1671/4885CA9 891/4885TNF 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.